[go: up one dir, main page]

JP2006265179A - Antihypertensive agent, and food and drink - Google Patents

Antihypertensive agent, and food and drink Download PDF

Info

Publication number
JP2006265179A
JP2006265179A JP2005086070A JP2005086070A JP2006265179A JP 2006265179 A JP2006265179 A JP 2006265179A JP 2005086070 A JP2005086070 A JP 2005086070A JP 2005086070 A JP2005086070 A JP 2005086070A JP 2006265179 A JP2006265179 A JP 2006265179A
Authority
JP
Japan
Prior art keywords
mushrooms
food
antihypertensive agent
rice bran
fiber raw
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2005086070A
Other languages
Japanese (ja)
Other versions
JP4783576B2 (en
Inventor
Yasuhide Hibino
康英 日比野
Hiroshi Iizuka
博 飯塚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NODA SHOKKIN KOGYO
NODA SHOKUKIN KOGYO KK
Original Assignee
NODA SHOKKIN KOGYO
NODA SHOKUKIN KOGYO KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NODA SHOKKIN KOGYO, NODA SHOKUKIN KOGYO KK filed Critical NODA SHOKKIN KOGYO
Priority to JP2005086070A priority Critical patent/JP4783576B2/en
Publication of JP2006265179A publication Critical patent/JP2006265179A/en
Application granted granted Critical
Publication of JP4783576B2 publication Critical patent/JP4783576B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Landscapes

  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

<P>PROBLEM TO BE SOLVED: To provide an antihypertensive agent and foods and drinks, causing no side effect, daily easily ingestible, and having high preventing and improving effects for hypertension. <P>SOLUTION: The antihypertensive agent and foods and drinks usable for preventing and improving hypertension are obtained by including components extracted from culture products obtained by culturing mycelium of Basidiomycete in a medium containing vegetable fibrous material. The extracted components preferably contain saccharide, protein, and water-soluble lignin. The vegetable fibrous material is preferably prepared from true grasses more preferably prepared from one or more selected from bagasse, maize foliage, wheat bran, rice bran, rice straw, cogon, striped bamboo, and bamboo. and as the basidiomycete, Ganoderma lucidum, Poria cocos, Ganoderma applanatum, Coriolus versicolor, Cortinellus shiitake, Pleurotus ostreatus, Grifola frondosa, Flammulina velutipes, Lyophyllum aggregatum, Hericium erinaceum, Agaricus blazei Murill and the like are used. <P>COPYRIGHT: (C)2007,JPO&INPIT

Description

本発明は、植物繊維質原料を含む培地に担子菌の菌糸体を培養して得られた培養物から抽出された成分を有効成分とする、高血圧症の予防、改善のために用いられる抗高血圧剤及び飲食品に関する。   The present invention relates to an antihypertension used for the prevention and improvement of hypertension, comprising as an active ingredient an ingredient extracted from a culture obtained by culturing mycelium of basidiomycetes in a medium containing plant fiber raw materials. The agent and food and drink.

一般に血圧は年齢とともに上昇し、60歳以上では軽症も含めると2人に1人は高血圧症であると言われ、10〜15年かけてゆっくり進行する代表的な生活習慣病である。   In general, blood pressure rises with age, and it is said that 1 of 2 people with hypertension, including mild cases, is a typical lifestyle-related disease that progresses slowly over 10 to 15 years.

世界保険機構(WHO)の専門委員会の基準では、高血圧症は、最大血圧(収縮期血圧)が160mmHg以上でかつ(又は)最小血圧(拡張期血圧)が95mmHg以上と定義されている。   According to the standards of the World Health Organization (WHO) technical committee, hypertension is defined as a maximum blood pressure (systolic blood pressure) of 160 mmHg or higher and / or a minimum blood pressure (diastolic blood pressure) of 95 mmHg or higher.

高血圧による障害は、全身の血管に動脈硬化を引き起こし、脳障害(脳出血、脳梗塞)、心臓障害(心肥大、心不全、狭心症、心筋梗塞)、腎障害(腎硬化症、腎不全)、眼の障害など全身に様々な障害を誘発し、生命を脅かすようになる。平成15年の人口動態統計(確定数)の概況によると死因の約30%が心疾患と脳血管疾患である。高血圧症は、自覚症状がほとんど無いことからサイレントキラーとも呼ばれ、恐れられている。   Damage caused by high blood pressure causes arteriosclerosis in the blood vessels of the whole body, brain damage (cerebral hemorrhage, cerebral infarction), heart damage (cardiac hypertrophy, heart failure, angina pectoris, myocardial infarction), kidney damage (renal sclerosis, renal failure), It induces various disorders throughout the body, such as eye disorders, and becomes life threatening. According to the overview of the 2003 demographic statistics (determined number), approximately 30% of deaths are from heart disease and cerebrovascular disease. Hypertension is also called a silent killer because it has almost no subjective symptoms and is feared.

高血圧症の90〜95%は、原因が特定できない本態性高血圧と言われている。本態性高血圧症は、遺伝因子と生活習慣(塩分の過剰摂取、肥満、運動不足、過度の飲酒、喫煙、ストレスなど)が複雑に絡み合って発症すると考えられる。   It is said that 90 to 95% of hypertension is essential hypertension whose cause cannot be specified. Essential hypertension is thought to develop by intricately intertwining genetic factors and lifestyle habits (overdose of salt, obesity, lack of exercise, excessive drinking, smoking, stress, etc.).

高血圧症の改善には、生活習慣を改善して、原因を除去することが重要であるが、減塩、ダイエット、運動、禁煙、酒量の適正化等の摂生を毎日続けることは容易なことではない。更にストレスを減らすことも現実的には困難である。   In order to improve hypertension, it is important to improve lifestyle and eliminate the cause, but it is not easy to continue daily intake such as salt reduction, diet, exercise, smoking cessation, optimization of alcohol consumption, etc. Absent. Furthermore, it is actually difficult to reduce stress.

しかも、このような生活習慣改善でも血圧が改善しない場合は薬剤治療が必要となる。高血圧症の薬剤としては、例えば利尿剤、交感神経抑制剤(β−ブロッカー、α−ブロッカー等)、カルシウム拮抗剤、アンジオテンシン(ACE)変換酵素阻害剤、アンジオテンシン受容体拮抗剤などが使用されている。目標通りの血圧低下が得られない場合には、これらの薬剤を組み合わせる必要もある。   Moreover, drug treatment is required if blood pressure does not improve even with such lifestyle improvements. As drugs for hypertension, for example, diuretics, sympathetic nerve inhibitors (β-blockers, α-blockers, etc.), calcium antagonists, angiotensin (ACE) converting enzyme inhibitors, angiotensin receptor antagonists, etc. are used. . These drugs need to be combined if blood pressure reduction cannot be achieved.

しかし、薬剤はそれ自体が体への負担となるばかりでなく、副作用を伴うことが多くQOLの低下を引き起こす可能性がある。   However, drugs are not only a burden on the body, but often have side effects, which can cause a decrease in quality of life.

食品の中には血圧低下作用のあるものが有り、薬剤治療の欠点を補う為に生活習慣改善と共に血圧低下作用のある食品を摂取することは有効な方法と考えられている。   Some foods have a blood pressure lowering effect, and it is considered to be an effective method to take a food having a blood pressure lowering effect together with lifestyle improvement in order to compensate for the drawbacks of drug treatment.

その一例として、かつお節の熱水抽出物から高血圧を改善する特定保健用食品が開発されている(非特許文献1参照)。   As an example, a food for specified health use that improves hypertension has been developed from a hot water extract of bonito (see Non-Patent Document 1).

また、食用きのこの中にも、マイタケ(非特許文献2参照)、ブナハリタケ(非特許文献3、4参照)、エノキタケ(特許文献1参照)、ハナビラタケ(特許文献2参照)、エリンギ(特許文献3参照)のように、血圧を低下させるものが報告されており、上記ブナハリタケからは、血圧が高目の人に対する特定保健用食品が開発されている。
藤田裕之、安本良一、長谷川晶康、大嶋一徳、かつお節オリゴペプチドによるヒトボランティアに対する血圧降圧作用(II)、薬理と治療、25 2161−2165(1997) Y. Kabir and S. Kimura、Dietary Mushrooms Reduce Blood Pressure in Spontaneously Hypertensive Rats(SHR)、J. Nutr. Sci. Vitaminol、35 91−94(1989) 佐藤拓、2002年版きのこ年鑑 259−265(2002) 土田隆、益子研士、長田秀幸、佐藤拓、薬理と治療 29 899−906(2001) 特開2004−89128号公報 特開2004−292414号公報 特開2002−176975号公報
In addition, among edible mushrooms, maitake (see Non-Patent Document 2), beech haritake (see Non-Patent Documents 3 and 4), enokitake (see Patent Document 1), Hanabiratake (see Patent Document 2), eringi (Patent Document 3) As described above, those that lower blood pressure have been reported, and from the above-mentioned Bunaharitake, food for specified health use for people with high blood pressure has been developed.
Hiroyuki Fujita, Ryoichi Yasumoto, Akiyasu Hasegawa, Kazunori Oshima, Antihypertensive effect on human volunteers with bonito oligopeptide (II), Pharmacology and treatment, 25 2161-2165 (1997) Y. Kabir and S. Kimura, Dietary Mushrooms Reduce Blood Pressure in Spontaneously Hypertensive Rats (SHR), J. Nutr. Sci. Vitaminol, 35 91-94 (1989) Taku Sato, 2002 Mushroom Yearbook 259-265 (2002) Takashi Tsuchida, Kenshi Masuko, Hideyuki Nagata, Taku Sato, Pharmacology and Treatment 29 899-906 (2001) JP 2004-89128 A JP 2004-292414 A JP 2002-176975 A

高血圧症は、10〜15年かけてゆっくり進行し、全身の動脈硬化を引き起こす誘因となり、脳血管障害、虚血性心疾患、解離性大動脈瘤、腎疾患、網膜症など多種の疾患のリスクファクターである。   Hypertension progresses slowly over 10 to 15 years, triggers generalized arteriosclerosis, and is a risk factor for various diseases such as cerebrovascular disorder, ischemic heart disease, dissecting aortic aneurysm, kidney disease, retinopathy, etc. is there.

原因の特定できない本態性高血圧症にならないためには、若い頃からの望ましい生活習慣が重要である。しかし、日常的に減塩、禁煙、運動、食事量や飲酒量の適正化等の摂生を続けることは容易ではなく、時間に追われ効率化を求められる複雑化した社会情勢の中ではストレスを減少させることも困難である。   Desirable lifestyle habits from a young age are important in order to prevent essential hypertension with unspecified causes. However, it is not easy to continue daily intake such as salt reduction, smoking cessation, exercise, optimization of meals and alcohol consumption, and it is stressful in a complicated social situation that requires time and efficiency. It is also difficult to reduce.

したがって、本発明は、副作用がなく日常的に手軽に摂取できる、高血圧症の予防、改善効果の高い抗高血圧剤及び飲食品を提供することにある。   Accordingly, an object of the present invention is to provide an antihypertensive agent and a food and drink having a high effect of preventing and improving hypertension that can be easily taken on a daily basis without side effects.

上記目的を達成するため、本発明の1つは、植物繊維質原料を含む培地に担子菌の菌糸体を培養して得られた培養物から抽出された成分を有効成分とする抗高血圧剤を提供するものである。   In order to achieve the above object, one of the present invention is an antihypertensive agent comprising, as an active ingredient, a component extracted from a culture obtained by culturing mycelium of basidiomycetes in a medium containing plant fiber raw materials. It is to provide.

また、本発明のもう1つは、植物繊維質原料を含む培地に担子菌の菌糸体を培養して得られた培養物から抽出された成分を含有し、高血圧症の予防、改善のために用いられる旨の表示を付した飲食品を提供するものである。   Another aspect of the present invention includes a component extracted from a culture obtained by culturing mycelia of basidiomycetes in a medium containing plant fiber raw materials, for the prevention and improvement of hypertension. The food / beverage products with the indication of being used are provided.

本発明の抗高血圧剤及び飲食品においては、前記抽出成分が、糖質、蛋白質、及び水溶性リグニンを含むものであることが好ましい。   In the antihypertensive agent and food / beverage products of this invention, it is preferable that the said extraction component is what contains saccharide | sugar, protein, and water-soluble lignin.

また、前記植物繊維質原料が、禾本科植物から調製されたものであることが好ましく、バガス、トウモロコシの茎葉、小麦ふすま、米糠、稲藁、茅、熊笹、及び竹から選ばれた1種又は2種以上であることがより好ましい。   In addition, the plant fiber raw material is preferably prepared from a plant family plant, one selected from bagasse, corn stover, wheat bran, rice bran, rice bran, rice bran, bear cocoon, and bamboo or Two or more types are more preferable.

更に、前記担子菌が、マンネン茸、ブクリョウ、コフキサルノコシカケ、カワラ茸、椎茸、ヒラ茸、マイ茸、エノキ茸、シメジ茸、ヤマブシ茸、及びアガリクスから選ばれたものであることが好ましい。   Furthermore, it is preferable that the basidiomycete is selected from mannen mushrooms, bukuro, kofukisarokoshikake, kawara mushrooms, shiitake mushrooms, hinoki mushrooms, mai mushrooms, enoki mushrooms, shimeji mushrooms, yamabushi mushrooms, and agaricus.

本発明の有効成分である、植物繊維質原料を含む培地に担子菌の菌糸体を培養して得られた培養物から抽出された成分は、植物繊維質原料中に含まれるセルロース、ヘミセルロース、リグニンなどが、培養期間中に担子菌の菌糸体が生産するセルラーゼ、フェノールオキシダーゼ、ラッカーゼ、パーオキシダーゼ、プロテアーゼなどの酵素により、消化、分解、及び縮合を起こして生成したペントース主体のプロテオグリカンに、酵素により変性して水溶性化した変性水溶性リグニンが複雑に結合した物質からなっている。この抽出成分は、後述する実施例に示されるように、高血圧自然発症ラットに経口投与すると、血圧の上昇を有意に抑制する。   Ingredients extracted from a culture obtained by culturing mycelium of basidiomycetes in a medium containing plant fiber raw materials, which are active ingredients of the present invention, are cellulose, hemicellulose, lignin contained in plant fiber raw materials Pentose-based proteoglycan produced by digestion, degradation, and condensation by enzymes such as cellulase, phenol oxidase, laccase, peroxidase, protease, etc. produced by mycelium of basidiomycetes during the culture period It consists of a substance in which denatured water-soluble lignin, which has been modified to become water-soluble, is bound in a complex manner. This extract component significantly suppresses an increase in blood pressure when orally administered to spontaneously hypertensive rats, as shown in Examples described later.

したがって、本発明の抗高血圧剤及び飲食品を摂取することにより、本態性高血圧を予防し、心疾患、脳血管障害、腎疾患、眼疾患等のリスク低減が期待される。   Therefore, by taking the antihypertensive agent and food and drink of the present invention, essential hypertension is prevented, and risk reduction of heart disease, cerebrovascular disorder, renal disease, eye disease and the like is expected.

また、すでに高血圧となった場合でも、本発明の抗高血圧剤を摂取することにより、血圧を低下させ、血圧のコントロールを容易にし、高血圧治療におけるQOL低下を防ぐことが期待される。   Even when hypertension has already occurred, taking the antihypertensive agent of the present invention is expected to lower blood pressure, facilitate blood pressure control, and prevent QOL reduction in hypertension treatment.

本発明の有効成分である上記抽出成分は、天然物から得られた物であり、化学薬品などにみられる副作用の心配はなく、日常生活の中で手軽に摂取することができる。   The extract component, which is an active ingredient of the present invention, is a product obtained from a natural product, and can be easily ingested in daily life without worrying about side effects seen in chemicals and the like.

また、既に高血圧症となった場合にも生活習慣改善に加えて、更なる降圧効果が期待でき血圧のコントロールを容易にする。   Moreover, in addition to improving lifestyle habits even when hypertension has already occurred, further antihypertensive effects can be expected and blood pressure control is facilitated.

更に、生活改善だけでは目標の血圧まで低下できない場合は、薬剤を服用する必要があるが、本発明の抗高血圧剤及び飲食品は、安全に手軽に接種できることから、薬剤と併用することで服薬量を低減化し、患者のQOL向上を可能とする。   Furthermore, if it is not possible to lower the target blood pressure simply by improving life, it is necessary to take the drug. However, since the antihypertensive agent and food and drink of the present invention can be safely and easily inoculated, Reduce volume and improve patient quality of life.

本発明に用いられる担子菌としては、特に限定されず、例えば、マンネン茸、ブクリョウ、コフキサルノコシカケ、カワラ茸などの薬用茸や、椎茸、ヒラ茸、マイ茸、エノキ茸、シメジ茸、ヤマブシ茸、アガリクスなどの食用茸など各種のものが挙げられる。この中でも、特にマンネン茸、椎茸が好ましく採用される。   The basidiomycetes used in the present invention are not particularly limited, for example, medicinal cocoons such as mannen moth, bukkyou, kofukisarokoshikake, kawara cocoon, shiitake mushroom, hirasu, mai kan, enoki mushroom, shimeji mushroom, yamabushi moth, Various foods such as edible rice cakes such as Agaricus are listed. Among these, mannen mushrooms and shiitake mushrooms are particularly preferably employed.

本発明では、これらの担子菌の菌糸体を、植物繊維質原料を含む培地を用いて培養し、その培養物から有効成分を抽出する。この場合、培地としては、固体培地、液体培地の何れも使用できる。培地に用いる植物繊維質原料としては、リグニンを含有する植物から調製されたものが好ましく用いられる。リグニンを含有する植物としては、禾本科植物、例えばバガス(さとうきびの搾り粕)、トウモロコシの茎葉、小麦ふすま、米糠、稲藁、茅などが好ましく用いられる。この他に、熊笹、竹なども使用できる。特に好ましくは、バガス、熊笹の茎葉、とうもろこしの茎から選ばれた少なくとも1種と、米糠とを含む培地が用いられる。また、培地には、必要に応じて他の栄養成分として、酵母エキス、乾燥酵母、クロレラ、スピルリナ、コーンミール、おからなどを添加混合してもよい。   In the present invention, mycelia of these basidiomycetes are cultured using a medium containing plant fiber raw material, and active ingredients are extracted from the culture. In this case, either a solid medium or a liquid medium can be used as the medium. As the plant fiber raw material used for the medium, one prepared from a plant containing lignin is preferably used. As the lignin-containing plant, a plant family such as bagasse (squeezed sugar cane), corn stover, wheat bran, rice bran, rice straw, and straw are preferably used. In addition, bears, bamboo, etc. can be used. Particularly preferably, a medium containing at least one kind selected from bagasse, bear shoots and corn stalks and rice bran is used. In addition, yeast extract, dry yeast, chlorella, spirulina, corn meal, okara, and the like may be added and mixed with the medium as other nutrient components as necessary.

担子菌の菌糸体の培養は、上記のような植物繊維質原料を含む培地に、前記担子菌の菌糸を接種して行う。固体培地の場合は、水分が60〜80%となるように調製し、常法に従い高圧蒸気滅菌した後、菌糸を接種し、例えば温度が18〜25℃に空調された培養室で3〜6か月培養する。こうして菌糸体が蔓延した培地は、温度処理室に移して変温処理を行うことが好ましい。変温処理は、例えば最初に30〜34℃で24〜48時間加温し、次に低温室に移して3〜5日間処理する。その後培養室に移すと子実体の発生が始まるが、この時点で培養を終了し、培養物を破砕機で破砕する。   The mycelium of basidiomycetes is cultured by inoculating the mycelium of basidiomycetes in a medium containing the above-mentioned plant fiber raw material. In the case of a solid medium, the water content is adjusted to 60 to 80%, sterilized by high-pressure steam according to a conventional method, and then inoculated with mycelia. Incubate for months. The medium in which the mycelium has spread is preferably transferred to a temperature treatment chamber and subjected to a temperature change treatment. In the temperature change treatment, for example, the mixture is first heated at 30 to 34 ° C. for 24 to 48 hours, and then transferred to a low temperature chamber and treated for 3 to 5 days. After that, when it is moved to a culture room, the generation of fruiting bodies starts. At this point, the culture is terminated and the culture is crushed with a crusher.

一方、液体培地の場合は、植物原料を細かく破砕し、必要に応じて米糠等の他の栄養成分を加え、原料が5〜20質量%となるように培地を調製した後、通気攪拌培養もしくは振盪培養により、好ましくは20〜28℃の温度で1週間〜2か月間程度培養を行う。培養は培地のpHが3.5〜5に低下し、培地中に菌糸が蔓延した状態で終了する。   On the other hand, in the case of a liquid medium, the plant raw material is finely crushed and, if necessary, other nutrient components such as rice bran are added, and the medium is prepared so that the raw material becomes 5 to 20% by mass, and then aeration stirring culture or By shaking culture, culture is preferably performed at a temperature of 20 to 28 ° C. for about 1 week to 2 months. The culture is terminated when the pH of the medium is lowered to 3.5 to 5 and the mycelium is prevalent in the medium.

培養終了後、菌糸体に内在する酵素を利用して菌糸体を自己消化させると共に培養物を抽出する。その好ましい方法として、固体培地の場合は培養が終了した培養物を破砕し、必要に応じて少量の水を加え、30〜60℃で3〜6時間処理し、菌糸体の酵素反応を進め、自己消化させる。次いで、この破砕物を50℃以上の温水又は熱水に浸潤させ、有効成分を抽出する。抽出は、例えば1.2Kg/cmの蒸気圧下で120℃というような加圧高温下で行うこともできる。こうして得られた抽出懸濁液を、好ましくは濾過または遠心分離して濾液又は上清を採取することにより、培地の分解物、菌糸体の代謝産物及び菌糸体細胞の分解物などを含む抽出液を得ることができる。 After completion of the culture, the mycelium is self-digested using an enzyme present in the mycelium and the culture is extracted. As a preferred method, in the case of a solid medium, the culture after culturing is crushed, a small amount of water is added as necessary, and the mixture is treated at 30 to 60 ° C. for 3 to 6 hours to advance the mycelial enzyme reaction, Let yourself digest. Subsequently, this crushed material is infiltrated with warm water or hot water of 50 ° C. or higher, and an active ingredient is extracted. The extraction can also be carried out under a high pressure such as 120 ° C. under a vapor pressure of 1.2 kg / cm 2 , for example. The extract suspension thus obtained is preferably filtered or centrifuged to collect a filtrate or a supernatant, whereby an extract containing a medium degradation product, a mycelium metabolite, a mycelium cell degradation product, or the like is obtained. Can be obtained.

一方、液体培養の場合は、培養物全体を30〜60℃で3〜6時間処理し、菌糸体を自己消化させ、液体の懸濁培養物を得る。次いで、必要に応じて少量の水を加え、50℃以上、場合によっては高圧条件下(例えば1.2Kg/cm2の蒸気圧下)に加熱し、抽出物を採取する。この抽出物を、必要に応じて濾過又は遠心分離して濾液又は上清を採取することにより、培地の分解物、菌糸体の代謝産物及び菌糸体細胞の分解物などを含む抽出液を得ることができる。 On the other hand, in the case of liquid culture, the whole culture is treated at 30 to 60 ° C. for 3 to 6 hours to self-digest the mycelium to obtain a liquid suspension culture. Then, if necessary, a small amount of water is added, and the mixture is heated to 50 ° C. or higher, sometimes under high pressure (for example, under a vapor pressure of 1.2 kg / cm 2 ), and the extract is collected. The extract is filtered or centrifuged as necessary to obtain a filtrate or supernatant, thereby obtaining an extract containing a degradation product of the medium, a mycelium metabolite, a mycelium cell degradation product, or the like. Can do.

こうして得られた抽出液は、そのまま又は濃縮して利用することもできるが、凍結乾燥や噴霧乾燥などの手段によって粉末化して利用することもできる。抽出液をそのまま又は濃縮して利用する場合には、液状又はゼリー状のドリンクタイプの製品とすることもできるし、そのまま各種の飲食品に添加して利用することもできる。抽出液を粉末化した場合には、常法によって、粉末、顆粒、錠剤、カプセル剤として製品化することができるし、各種の飲食品に添加して利用することもできる。   The extract thus obtained can be used as it is or after being concentrated, but can also be used by pulverizing it by means such as freeze drying or spray drying. When the extract is used as it is or after being concentrated, it can be made into a liquid or jelly-like drink type product, or it can be added to various foods and drinks as it is. When the extract is pulverized, it can be commercialized as powders, granules, tablets, capsules by conventional methods, and can be used by adding to various foods and drinks.

本発明の抗高血圧剤又は飲食品は、上記のようにして調製された粉末、顆粒、錠剤、カプセル剤、又はドリンクとして製品化でき、あるいは各種の飲食品に添加して血圧上昇抑制効果が期待できる飲食品として製品化することもできる。   The antihypertensive agent or food and drink of the present invention can be commercialized as powders, granules, tablets, capsules, or drinks prepared as described above, or added to various foods and drinks and expected to suppress blood pressure rise. It can also be commercialized as a possible food and drink.

本発明の飲食品は、高血圧症の予防、改善のために用いられる旨の表示を付したものであるが、ここで、「表示を付した」とは、製品の容器、袋、箱等の包装材料等に直接表示されたものだけでなく、製品の袋や箱等に同封された印刷物、製品パンフレット、代理店等に対する販促資料、更にはインターネットのホームページ等に記載された製品情報等に表示されたものを含む意味である。   The food and drink of the present invention is labeled with a label indicating that it is used for prevention and improvement of hypertension. Here, “labeled” means a product container, bag, box, etc. Not only those displayed directly on packaging materials, but also printed information enclosed in product bags and boxes, product brochures, sales promotion materials for agents, etc., and also displayed on product information described on the Internet website, etc. It is meant to include

本発明の有効成分である前記抽出物(植物繊維質原料を含む培地に担子菌の菌糸体を培養して得られた培養物から抽出された成分)は、糖質を主体とした物質であるが、次のような物理化学的性質を有していることが確認された。   The extract as an active ingredient of the present invention (a component extracted from a culture obtained by culturing mycelia of basidiomycetes in a medium containing plant fiber raw material) is a substance mainly composed of carbohydrates. Has been confirmed to have the following physicochemical properties.

(1) 分子量:100万以下
(2) 化学組成 糖質:30〜50%
蛋白質:8〜15%
水溶性リグニン:20〜40%
(1) Molecular weight: 1 million or less
(2) Chemical composition Carbohydrate: 30-50%
Protein: 8-15%
Water-soluble lignin: 20-40%

なお、マンネン茸を用いて得られた上記培養抽出物(粉末)について安全性を試験した結果は次の通りである。
(A) 急性毒性試験(最小致死量;LDL
ラット単回経口投与 雄:22500mg/Kg 以上
雌:22500mg/Kg 以上
マウス単回経口投与 雄:2000mg/Kg 以上
雌:2000mg/Kg 以上
(B) ラット3ヶ月反復経口投与試験(最大無作用量)
雄:3610mg/Kg
雌:4190mg/Kg
In addition, the result of having tested safety | security about the said culture extract (powder) obtained using the mannen koji is as follows.
(A) Acute toxicity test (minimum lethal dose; LDL 0 )
Rat single oral administration Male: 22500mg / Kg or more
Female: 22500mg / Kg or more Single oral administration of mouse Male: 2000mg / Kg or more
Female: 2000mg / Kg or more
(B) Rat 3-month repeated oral administration test (maximum no-effect level)
Male: 3610mg / Kg
Female: 4190mg / Kg

また、本発明の抗高血圧剤及び飲食品の有効投与量は、前記抽出物換算で、経口摂取において成人1日当たり1〜10gである。投与量がこれよりも少ないと、生体内で血圧上昇抑制効果が十分に得られず、投与量がこれよりも多いと、軟便又は腹部膨満感が生じることがある。ただし、投与量が上記より多くても安全性には問題がない。   Moreover, the effective dosage of the antihypertensive agent and food / beverage products of this invention is 1-10g per day for an adult in oral intake in conversion of the said extract. If the dose is smaller than this, the effect of suppressing blood pressure elevation cannot be sufficiently obtained in vivo, and if the dose is larger than this, loose stool or abdominal bloating may occur. However, there is no problem in safety even if the dose is larger than the above.

実施例1
(1)マンネンタケ菌の固体培養
バガス90%、脱脂米糠10%を配合し、水分を70%となるように調整して固形培地を作り、常法通り高圧蒸気滅菌した。これにマンネンタケの菌糸を接種し、25℃に温度調節した培養室内で3ヶ月培養し、培地中に菌糸体が蔓延した後、温度処理室に移して35℃で24時間加温し、次いで10℃の低温室で3日間処理した。その後、培養室で3日間培養し、培地を破砕機で親指程度の大きさに破砕した。破砕した培地を40℃で6時間処理し、自己消化を促進させた後、抽出タンクに詰め、60℃の温水を循環させながら16時間抽出した。得られた抽出液をカートリッジフィルターで濾過し、更にメンブランフィルターで濾過除菌後、濃縮し、凍結乾燥により褐色の粉末を得た。以下、この粉末を「本粉末」とする。
Example 1
(1) Solid culture of Mannentake fungus 90% bagasse and 10% defatted rice bran were mixed, and a solid medium was prepared by adjusting the water content to 70%. This was inoculated with mycelia mushrooms and cultured for 3 months in a culture chamber adjusted to 25 ° C. After the mycelium had spread in the medium, it was transferred to a temperature treatment chamber and heated at 35 ° C for 24 hours, and then 10 ° C. Treated in a cold room at 3 ° C for 3 days. Thereafter, the cells were cultured in a culture room for 3 days, and the medium was crushed to the size of a thumb with a crusher. The crushed medium was treated at 40 ° C. for 6 hours to promote autolysis, then packed in an extraction tank, and extracted for 16 hours while circulating hot water at 60 ° C. The obtained extract was filtered through a cartridge filter, further sterilized by filtration through a membrane filter, concentrated, and freeze-dried to obtain a brown powder. Hereinafter, this powder is referred to as “present powder”.

本粉末の成分を分析した結果以下の通りであった。   As a result of analyzing the components of this powder, it was as follows.

糖質 :40%(フェノール硫酸法)
蛋白質 :12%(セミミクロケルダール法)
水溶性リグニン :30%(アセチルブロマイド法)
無機質 :13%(直接灰化法)
Carbohydrate: 40% (phenol sulfate method)
Protein: 12% (semi-micro Kjeldahl method)
Water-soluble lignin: 30% (acetyl bromide method)
Inorganic: 13% (direct ashing method)

(2)血圧上昇抑制効果
本粉末について高血圧自然発症ラット(SHR)の血圧上昇抑制効果を測定した。SHRにおける高血圧発症は、人での本態性高血圧症発症の病体モデルと考えられる。
(2) Blood pressure increase inhibitory effect The blood pressure increase inhibitory effect of the spontaneously hypertensive rat (SHR) was measured about this powder. The development of hypertension in SHR is considered to be a pathological model of the development of essential hypertension in humans.

(i)実験動物
4週齢のSHR((株)埼玉実験動物供給社製)を、購入後、温度、湿度、光照射時間をコントロールした動物室で馴化させた。動物は、対照群と本粉末群に無作為に選別した。餌は粉末CE−2(商品名、(株)埼玉実験動物供給社製)を与えた。
(i) Experimental animals After purchase, 4 weeks old SHR (manufactured by Saitama Experimental Animal Supply Co., Ltd.) was acclimated in an animal room in which temperature, humidity and light irradiation time were controlled. Animals were randomly selected into a control group and this powder group. The food was powder CE-2 (trade name, manufactured by Saitama Experimental Animal Supply Co., Ltd.).

(ii)投与方法
1日絶食させた後、対照群には粉末CE-2を、本粉末群には粉末CE−2に0.5%の本粉末を混合した餌を10週間与えた。
(ii) Administration method After fasting for one day, the control group was fed with powder CE-2, and the main powder group was fed with a powder CE-2 mixed with 0.5% main powder for 10 weeks.

(iii)血圧、摂食量および体重測定
血圧は非観式血圧測定器(商品名 MK2000:室町機械製)を用い収縮期血圧を測定した。各ラットにおいて毎回5回測定し、その平均値を記録した。
(iii) Measurement of blood pressure, food intake and body weight As for blood pressure, systolic blood pressure was measured using a non-invasive blood pressure measuring device (trade name: MK2000: manufactured by Muromachi Kikai). Each rat was measured 5 times and the average value was recorded.

摂食量および体重は毎日測定した。   Food intake and body weight were measured daily.

(iv)mRNA量の測定
10週間の血圧測定後、腎皮質、腎髄質、左心室および腹部大動脈より抽出した total RNA を用いて Real-time RT-PCR を行い、fibronectin(フィブロネクチン)のmRNA量を測定した。
(iv) Measurement of mRNA level
After measuring blood pressure for 10 weeks, real-time RT-PCR was performed using total RNA extracted from the renal cortex, renal medulla, left ventricle and abdominal aorta, and the amount of fibronectin (fibronectin) mRNA was measured.

(v)血圧測定結果
図1は、SHRにおける血圧の週齢変化を測定した結果である。図1中、縦軸は血圧、横軸は週齢であり、○はCE−2だけの飼料を投与した群(以下「CE−2群」とする)、●はCE−2に本粉末を0.5%添加した飼料を投与した群(以下「MAK群」とする)。対照であるCE−2群では血圧は週齢があがると共に上昇した。同図に示したように本粉末を含むMAK群では摂食2週目より持続的な血圧上昇抑制(約-20mmHg)が認められ、この差は両群間で分散が等しくないと仮定したt検定により有意であった。
(v) Blood pressure measurement results FIG. 1 shows the results of measuring changes in blood pressure with age in SHR. In FIG. 1, the vertical axis represents blood pressure, the horizontal axis represents age, ○ represents a group administered with CE-2 only feed (hereinafter referred to as “CE-2 group”), and ● represents this powder on CE-2. A group to which a feed supplemented with 0.5% was administered (hereinafter referred to as “MAK group”). In the CE-2 group as a control, blood pressure increased with age. As shown in the figure, in the MAK group containing this powder, a sustained increase in blood pressure (about -20 mmHg) was observed from the 2nd week of feeding, and this difference was assumed to have an equal variance between the two groups. Significant by test.

(vi)摂食量および体重
図2に摂食量の推移を、図3に体重変化を示した。図2中、縦軸は摂食量、横軸は週齢を示し、図3中、縦軸は体重、横軸は週齢を示す。○及び●は前記と同じ意味である。
(vi) Food intake and body weight FIG. 2 shows changes in food intake and FIG. 3 shows changes in body weight. In FIG. 2, the vertical axis represents food intake, the horizontal axis represents age, and in FIG. 3, the vertical axis represents body weight, and the horizontal axis represents age. ○ and ● have the same meaning as described above.

図2,3の結果から、摂食量及び体重変化は、対照であるCE−2群と本粉末を含むMAK群とで差は認められなかった。   From the results of FIGS. 2 and 3, there was no difference in food intake and body weight change between the control CE-2 group and the MAK group containing the present powder.

(vii)mRNA量測定結果
図4に、fibronectin(フィブロネクチン)のmRNA量の測定結果を示した。図4中、縦軸はCE−2群を1としてMAK群を相対値で示したmRNA量、横軸は測定した組織を示している。白の棒グラフはCE−2群、黒の棒グラフはMAK群を表す。
(vii) Measurement result of mRNA amount FIG. 4 shows the measurement result of the amount of mRNA of fibronectin (fibronectin). In FIG. 4, the vertical axis represents the amount of mRNA with the CE-2 group as 1, and the MAK group as a relative value, and the horizontal axis represents the measured tissue. The white bar graph represents the CE-2 group, and the black bar graph represents the MAK group.

図4に示すように、腎皮質(cortex)、腎髄質(medulla)、左心室(heart)および腹部大動脈(ventral arota)について測定したところ、本粉末を投与したMAK群では、FibronectinのmRNA量が本粉末を投与したMAK群で心臓(左心室)において約50%低下していた。   As shown in FIG. 4, the renal cortex, renal medulla, left ventricle (heart) and ventral arota were measured. In the MAK group administered with this powder, the amount of fibronectin mRNA was In the MAK group to which this powder was administered, the heart (left ventricle) was reduced by about 50%.

実施例2
椎茸の菌糸体を実施例1と同様な培地に接種して固体培養を行い、実施例1と同様な処理を行って抽出液を得た。この抽出液の凍結乾燥品の成分は以下の通りであった。
Example 2
The mycelium of shiitake mushrooms were inoculated into the same medium as in Example 1 to perform solid culture, and the same treatment as in Example 1 was performed to obtain an extract. The components of the freeze-dried product of this extract were as follows.

糖質 :35%
蛋白質 :11%
水溶性リグニン :35%
無機質 :12%
この抽出物は実施例1と同様にSHRの血圧上昇を抑制した。
Carbohydrate: 35%
Protein: 11%
Water-soluble lignin: 35%
Inorganic: 12%
This extract suppressed the increase in blood pressure of SHR as in Example 1.

実施例3
熊笹の葉、茎をよく洗い乾燥して破砕し、これに米糠を質量比で2割となるように混ぜて固形培地を作り、これに椎茸の菌糸体を培養し、実施例1と同様の方法で抽出液を得た。この抽出液は実施例1と同様にSHRの血圧上昇を抑制した。
Example 3
The leaves and stems of kumamushi are washed well, dried and crushed, and then mixed with rice bran so that the mass ratio is 20%, a solid medium is prepared, and the mycelium of shiitake mushroom is cultured on this, and the same as in Example 1 The extract was obtained by the method. This extract suppressed the increase in blood pressure of SHR as in Example 1.

実施例4
水に対し、ミキサーで細かく破砕したバガス100g、米糠20g、イーストエキス5gの割合で加えた液体培地を調整し、常法通り高圧蒸気滅菌を行い、椎茸の菌糸体を接種した。23℃で2週間、通気(通気量:5リットル/min)、撹拌(50rpm)培養した後、培養物を40℃で3時間加温し菌糸の酵素による自己消化反応を進行させた。その後80℃で1時間加熱殺菌し代謝物を抽出した。抽出物は3000rpmで30分間遠心分離し沈殿物を除き、更に10000rpmで遠心し、褐色の液を得た。この抽出液を凍結乾燥したものは以下の組成であった。
Example 4
A liquid medium was prepared by adding 100 g of bagasse finely crushed with a mixer at a ratio of 20 g of rice bran and 5 g of yeast extract, followed by autoclaving as usual, and inoculating shiitake mycelium. After aeration (aeration rate: 5 liters / min) and stirring (50 rpm) for 2 weeks at 23 ° C., the culture was heated at 40 ° C. for 3 hours to allow the mycelial enzyme to self-digest. Thereafter, the mixture was sterilized by heating at 80 ° C. for 1 hour to extract metabolites. The extract was centrifuged at 3000 rpm for 30 minutes to remove the precipitate, and further centrifuged at 10,000 rpm to obtain a brown liquid. This extract was freeze-dried and had the following composition.

糖質 :35%
水溶性リグニン :40%
蛋白質 :12%
その他 :13%
本品は実施例1と同様SHRの血圧上昇を抑制した。
Carbohydrate: 35%
Water-soluble lignin: 40%
Protein: 12%
Other: 13%
This product suppressed the increase in blood pressure of SHR as in Example 1.

実施例5
51歳男性の例:
父親が本態性高血圧で若年より抗高血圧薬を常用していたため、本人も血圧上昇を気遣って生活習慣には気を配っていたが、数年前から血圧が上昇傾向にあり、収縮期血圧が130〜140mmHg、拡張期血圧が96mmHgとなった。実施例1で得られた抽出物乾燥品を2g/日、2週間飲用したところ、収縮期血圧が120mmHg、拡張期血圧が85mmHg前後となった。
Example 5
Example of a 51 year old man:
Since his father had essential hypertension and he regularly used antihypertensive drugs from a young age, he himself was concerned about blood pressure rise and he was aware of lifestyle habits, but blood pressure has been on the rise for several years, and systolic blood pressure has 130-140 mmHg, diastolic blood pressure was 96 mmHg. When the dried extract obtained in Example 1 was drunk at 2 g / day for 2 weeks, the systolic blood pressure was 120 mmHg and the diastolic blood pressure was around 85 mmHg.

実施例6
63歳男性の例:
本態性高血圧で動悸亢進のため通院し、最大血圧が200mmHgであった。動悸鎮静薬と共に、実施例2で得られた粉末を1g/日、3ヶ月摂取したところ、最大血圧120mmHg、最小血圧60mmHgに低下した。
Example 6
Example of a 63 year old man:
The patient went to the hospital for essential hypertension and increased palpitations, and the maximum blood pressure was 200 mmHg. When the powder obtained in Example 2 was ingested 1 g / day for 3 months together with the palliative sedative, the maximum blood pressure decreased to 120 mmHg and the minimum blood pressure to 60 mmHg.

本発明は、高血圧症患者や高血圧症の虞れのある人に対して、日常的に摂取させることにより、血圧の上昇を抑制して、高血圧症の予防、治療を図るための医薬品、健康食品等として利用することができる。   The present invention relates to a pharmaceutical product and a health food for preventing hypertension prevention and treatment by suppressing a rise in blood pressure by daily intake for hypertension patients and persons with a possibility of hypertension Etc. can be used.

実施例1で得られた粉末を0.5%含有する餌を高血圧自然発症ラット(SHR)に経口摂取させた場合の血圧の経時変化を測定した結果を示す図表である。It is a graph which shows the result of having measured the time-dependent change of the blood pressure when the food containing 0.5% of the powder obtained in Example 1 is orally ingested by the spontaneously hypertensive rat (SHR). 実施例1で得られた粉末を0.5%含有する餌を高血圧自然発症ラット(SHR)に経口摂取させた場合の摂食量の経時変化を測定した結果を示す図表である。It is a graph which shows the result of having measured the time-dependent change of the amount of food intake when the food containing 0.5% of the powder obtained in Example 1 was orally ingested by spontaneously hypertensive rats (SHR). 実施例1で得られた粉末を0.5%含有する餌を高血圧自然発症ラット(SHR)に経口摂取させた場合の体重の経時変化を測定した結果を示す図表である。It is a graph which shows the result of having measured the time-dependent change of the body weight when the food containing 0.5% of the powder obtained in Example 1 was orally ingested by spontaneously hypertensive rats (SHR). 実施例1で得られた粉末を0.5%含有する餌を高血圧自然発症ラット(SHR)に10週間経口摂取させた後の腎皮質、腎髄質、左心室および腹部大動脈のfibronectinに対するmRNA量測定結果を示す図表である。The results of measuring the amount of mRNA for fibronectin in the renal cortex, renal medulla, left ventricle and abdominal aorta after ingesting the diet containing 0.5% of the powder obtained in Example 1 to spontaneously hypertensive rats (SHR) for 10 weeks. It is a chart to show.

Claims (10)

植物繊維質原料を含む培地に担子菌の菌糸体を培養して得られた培養物から抽出された成分を有効成分とする抗高血圧剤。   An antihypertensive agent comprising as an active ingredient an ingredient extracted from a culture obtained by culturing mycelium of basidiomycetes in a medium containing plant fiber raw materials. 前記抽出成分が、糖質、蛋白質、及び水溶性リグニンを含むものである請求項1記載の抗高血圧剤。   The antihypertensive agent according to claim 1, wherein the extracted component contains a carbohydrate, a protein, and a water-soluble lignin. 前記植物繊維質原料が、禾本科植物から調製されたものである請求項1又は2記載の抗高血圧剤。   3. The antihypertensive agent according to claim 1 or 2, wherein the plant fiber raw material is prepared from a plant of the family genus. 前記植物繊維質原料が、バガス、トウモロコシの茎葉、小麦ふすま、米糠、稲藁、茅、熊笹、及び竹から選ばれた1種又は2種以上である請求項1又は2記載の抗高血圧剤。   The antihypertensive agent according to claim 1 or 2, wherein the plant fiber raw material is one or more selected from bagasse, corn stover, wheat bran, rice bran, rice bran, rice bran, kumabana, and bamboo. 前記担子菌が、マンネン茸、ブクリョウ、コフキサルノコシカケ、カワラ茸、椎茸、ヒラ茸、マイ茸、エノキ茸、シメジ茸、ヤマブシ茸、及びアガリクスから選ばれたものである請求項1〜4のいずれか1つに記載の抗高血圧剤。   The basidiomycete is selected from Mannen mushrooms, Bukuryo, Kofukisarokoshikake, Kawara mushrooms, Shiitake mushrooms, Hira mushrooms, Mai mushrooms, Enoki mushrooms, Shimeji mushrooms, Yamabushi mushrooms, and Agaricus. The antihypertensive agent according to one. 植物繊維質原料を含む培地に担子菌の菌糸体を培養して得られた培養物から抽出された成分を含有し、高血圧症の予防、改善のために用いられる旨の表示を付した飲食品。   A food and drink product that contains ingredients extracted from a culture obtained by culturing mycelia of basidiomycetes in a medium containing plant fiber raw materials and that is used for the prevention and improvement of hypertension . 前記抽出成分が、糖質、蛋白質、及び水溶性リグニンを含むものである請求項6記載の飲食品。   The food / beverage product according to claim 6, wherein the extracted component contains a sugar, a protein, and a water-soluble lignin. 前記植物繊維質原料が、禾本科植物から調製されたものである請求項6又は7記載の飲食品。   The food or drink according to claim 6 or 7, wherein the plant fiber raw material is prepared from a plant of the family genus. 前記植物繊維質原料が、バガス、トウモロコシの茎葉、小麦ふすま、米糠、稲藁、茅、熊笹、及び竹から選ばれた1種又は2種以上である請求項6又は7記載の飲食品。   The food or drink according to claim 6 or 7, wherein the plant fiber raw material is one or more selected from bagasse, corn stover, wheat bran, rice bran, rice bran, rice bran, kumabushi, and bamboo. 前記担子菌が、マンネン茸、ブクリョウ、コフキサルノコシカケ、カワラ茸、椎茸、ヒラ茸、マイ茸、エノキ茸、シメジ茸、ヤマブシ茸、及びアガリクスから選ばれたものである請求項6〜9のいずれか1つに記載の飲食品。   The basidiomycete is selected from Mannen mushrooms, Bukurou, Kofukisarokoshikake, Kawara mushrooms, Shiitake mushrooms, Japanese holly mushrooms, Mai mushrooms, Enoki mushrooms, Shimeji mushrooms, Yamabushi mushrooms, and Agaricus. Food and drink according to one.
JP2005086070A 2005-03-24 2005-03-24 Antihypertensive Expired - Lifetime JP4783576B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2005086070A JP4783576B2 (en) 2005-03-24 2005-03-24 Antihypertensive

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2005086070A JP4783576B2 (en) 2005-03-24 2005-03-24 Antihypertensive

Publications (2)

Publication Number Publication Date
JP2006265179A true JP2006265179A (en) 2006-10-05
JP4783576B2 JP4783576B2 (en) 2011-09-28

Family

ID=37201514

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2005086070A Expired - Lifetime JP4783576B2 (en) 2005-03-24 2005-03-24 Antihypertensive

Country Status (1)

Country Link
JP (1) JP4783576B2 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009102256A (en) * 2007-10-23 2009-05-14 Noda Shokukin Kogyo Kk Method for producing extract material of cultured mycelium and device for culturing mycelium
JP2011102300A (en) * 2007-07-27 2011-05-26 National Agriculture & Food Research Organization Angiotensin i converting enzyme inhibitor from wheat bran, barley bran and rice bran
JP2015013840A (en) * 2013-07-08 2015-01-22 野田食菌工業株式会社 Sleep-improving agent
CN107485688A (en) * 2016-06-12 2017-12-19 贵定廖氏古方科技有限公司 Treat uremic Chinese medicine
CN113016971A (en) * 2019-12-09 2021-06-25 南京宿根花卉植物园有限公司 Solid beverage for reducing blood pressure

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5446859A (en) * 1977-09-22 1979-04-13 Japan Synthetic Rubber Co Ltd Production of health food
JPS57170173A (en) * 1981-04-11 1982-10-20 Chiyokichi Iizuka Preparation of powdery food containing effective component of mycelia of edible mushroom and roughage
JPS5826820A (en) * 1981-08-11 1983-02-17 Asahi Denka Kogyo Kk Hypotensive substance
JPS6023826B2 (en) * 1981-12-21 1985-06-10 均 長岡 Health drink manufacturing method
JPS63202356A (en) * 1987-02-17 1988-08-22 Hitoshi Nagaoka Extraction of useful ingredient from mecelia of flammulina velutipes (mushroom) and bagasse medium
JPH02107171A (en) * 1988-10-14 1990-04-19 Hitoshi Nagaoka Preparation of food containing dietary fiber
JPH03118328A (en) * 1989-09-29 1991-05-20 Shimaya:Kk Physiologically active substance for preventing and treating hypertension, hyperlipidemia and obesity
JPH07126276A (en) * 1993-10-28 1995-05-16 New Oji Paper Co Ltd Physiologically active substance obtained from basidiomycetes
JPH07267975A (en) * 1994-03-30 1995-10-17 New Oji Paper Co Ltd Production of substance containing angiotensinase inhibitor
JPH11228441A (en) * 1998-02-19 1999-08-24 Noda Shokukin Kogyo Kk Antioxidant function potentiator for living body
JP2002029995A (en) * 1999-12-06 2002-01-29 Kirin Brewery Co Ltd Pharmacological composition having vasodepressor activity

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5446859A (en) * 1977-09-22 1979-04-13 Japan Synthetic Rubber Co Ltd Production of health food
JPS57170173A (en) * 1981-04-11 1982-10-20 Chiyokichi Iizuka Preparation of powdery food containing effective component of mycelia of edible mushroom and roughage
JPS5826820A (en) * 1981-08-11 1983-02-17 Asahi Denka Kogyo Kk Hypotensive substance
JPS6023826B2 (en) * 1981-12-21 1985-06-10 均 長岡 Health drink manufacturing method
JPS63202356A (en) * 1987-02-17 1988-08-22 Hitoshi Nagaoka Extraction of useful ingredient from mecelia of flammulina velutipes (mushroom) and bagasse medium
JPH02107171A (en) * 1988-10-14 1990-04-19 Hitoshi Nagaoka Preparation of food containing dietary fiber
JPH03118328A (en) * 1989-09-29 1991-05-20 Shimaya:Kk Physiologically active substance for preventing and treating hypertension, hyperlipidemia and obesity
JPH07126276A (en) * 1993-10-28 1995-05-16 New Oji Paper Co Ltd Physiologically active substance obtained from basidiomycetes
JPH07267975A (en) * 1994-03-30 1995-10-17 New Oji Paper Co Ltd Production of substance containing angiotensinase inhibitor
JPH11228441A (en) * 1998-02-19 1999-08-24 Noda Shokukin Kogyo Kk Antioxidant function potentiator for living body
JP2002029995A (en) * 1999-12-06 2002-01-29 Kirin Brewery Co Ltd Pharmacological composition having vasodepressor activity

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011102300A (en) * 2007-07-27 2011-05-26 National Agriculture & Food Research Organization Angiotensin i converting enzyme inhibitor from wheat bran, barley bran and rice bran
JP2009102256A (en) * 2007-10-23 2009-05-14 Noda Shokukin Kogyo Kk Method for producing extract material of cultured mycelium and device for culturing mycelium
JP4673354B2 (en) * 2007-10-23 2011-04-20 野田食菌工業株式会社 Method for producing mycelium culture extract and mycelium culture apparatus
JP2015013840A (en) * 2013-07-08 2015-01-22 野田食菌工業株式会社 Sleep-improving agent
CN107485688A (en) * 2016-06-12 2017-12-19 贵定廖氏古方科技有限公司 Treat uremic Chinese medicine
CN113016971A (en) * 2019-12-09 2021-06-25 南京宿根花卉植物园有限公司 Solid beverage for reducing blood pressure

Also Published As

Publication number Publication date
JP4783576B2 (en) 2011-09-28

Similar Documents

Publication Publication Date Title
TWI386485B (en) Tramete versicolor and its extract and use thereof
CN102488278A (en) Composite fungus nutrient solution with bifunctional health care effect
CN110771825A (en) Comprehensive nutrition powder for reducing fat, blood sugar, blood pressure and blood fat and preparation method thereof
JP2007306898A (en) Functional food using cordyceps sinensis (berkeley) saccardo, and method for producing the same
KR20150137674A (en) Manufacturing method of functional fermented brown rice vinegar
KR101105591B1 (en) Blood sugar lowering functional rice low-sugar rice and its manufacturing method
KR101610466B1 (en) A composition containing complex extracts comprising Vitis sp. and Schisandra chinensis for preventing or treating metabolic syndrome-related diseases
CN105661515B (en) A kind of ferment lozenge for preventing three high diseases and preparation method thereof
CN107890117A (en) A kind of compound oligomeric peptide nutrient powder of WPC
JP4132635B2 (en) Uninactivated enzyme-enhanced composition
CN1527717A (en) Remedies
KR101759494B1 (en) Preparation method for sodium-reduced soy sauce with anti-hypertensive activity
JP4602674B2 (en) Maltase inhibitor
JP5144112B2 (en) Brain protectant
JP5993112B2 (en) Antidepressant
KR20140017932A (en) Composition of diabetes-improving effective constituents by fermentation products of the trifoliate orange
JP4783576B2 (en) Antihypertensive
JP2011184349A (en) Frequent urination-ameliorating composition, healthy food and blood flow-ameliorating composition
JP3628999B2 (en) Anonymous tea and its manufacturing method
JP2002087981A (en) Improving agent for metabolic disorder against sugar and lipid
JP2020005539A (en) Culture medium, method for obtaining useful substance, useful substance and use therefor
JP4368540B2 (en) Osteomalacia preventive agent
KR101307051B1 (en) Nature seasoning using micro algae protein hydrolysate and the manufacturing method thereof
JP4269547B2 (en) Hypoglycemic agent and method for producing the same
JP2009024027A (en) Physiologically active composition

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090609

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090810

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20090810

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100629

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100830

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20110518

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110705

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110711

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140715

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4783576

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250